Medpace (NASDAQ:MEDP) VP Susan Burwig Sells 7,500 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) VP Susan Burwig sold 7,500 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. The trade was a 10.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Medpace Trading Up 2.5%

Medpace stock opened at $585.49 on Thursday. The firm has a market cap of $16.34 billion, a price-to-earnings ratio of 34.32, a PEG ratio of 2.55 and a beta of 1.15. The stock has a fifty day simple moving average of $501.76 and a two-hundred day simple moving average of $493.30. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same period in the prior year, the company posted $3.10 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on MEDP shares. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Truist Financial raised their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and lifted their target price for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, TD Cowen boosted their target price on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Two analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $584.18.

Hedge Funds Weigh In On Medpace

Institutional investors and hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC grew its stake in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after acquiring an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Medpace in the second quarter worth approximately $296,000. Finally, M&T Bank Corp increased its stake in shares of Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.